methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate
• 英文别名: methyl 1-[[4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]thiophen-2-yl]methyl]azetidine-3-carboxylate
• 化学式: C₂₆H₂₅N₃O₄S
• 分子量: 475.568
• InChiKey: ADFNSISCIFQSSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate 在 sodium hydroxide 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 以86%的产率得到1-[[4-乙基-5-[5-(4-苯氧基苯基)-1,2,4-恶二唑-3-基]-2-噻吩基]甲基]-3-氮杂环丁烷羧酸
  参考文献：
  名称：

  Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist

  摘要：

  Modulators of sphingosine phosphate receptor-1 (S1P(1)) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based S1P(1) agonist 1-({4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid (CS-2100, 8) showing potent S1P(1) agonist activity against S1P(3) and an excellent in vivo potency. We report herein the synthesis of CS-2100 (8) and pharmacological effects such as S1P(1) and S1P(3) agonist activity in vitro, peripheral blood lymphocyte lowering effects and the suppressive effects on adjuvant-induced arthritis and experimental autoimmune encephalomyelitis (EAE) in animal models. The pharmacokinetic data were also reported. CS-2100 (8) had >5000-fold greater agonist activity for human S1P(1) (EC50; 4.0 nM) relative to S1P(3) (EC50; >20000 nM). Following administration of single oral doses of 0.1 and 1 mg/kg of CS-2100 (8) in rats, lymphocyte counts decreased significantly, with a nadir at 8 and/or 72 h post-dose and recovery to vehicle control levels by 24-48 h post-dose. CS-2100 (8) is efficacious in the adjuvant-induced arthritis model in rats (ID50; 0.44 mg/kg). In the EAE model compared to the vehicle-treated group, significant decreases in the cumulative EAE scores were observed for 0.3 and 1 mg/kg CS-2100 (8) groups in mice. While CS-2100 (8) showed potent efficacy in various animal disease models, it was also revealed that the central 1,2,4-oxadiazole ring of CS-2100 (8) was decomposed by enterobacteria in intestine of rats and monkeys, implicating the latent concern about an external susceptibility in its metabolic process in the upcoming clinical studies. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.022
• 作为产物：
  描述：

  ((4-bromothiophene-2-yl)methoxy)(tert-butyl)dimethylsilane 在 正丁基锂 、 1,3-bis[(diphenylphosphino)propane]dichloronickel(II) 、 四溴化碳 、 盐酸羟胺 、 四丁基氟化铵 、 羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 22.0h， 生成 methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist

  摘要：

  Modulators of sphingosine phosphate receptor-1 (S1P(1)) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based S1P(1) agonist 1-({4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid (CS-2100, 8) showing potent S1P(1) agonist activity against S1P(3) and an excellent in vivo potency. We report herein the synthesis of CS-2100 (8) and pharmacological effects such as S1P(1) and S1P(3) agonist activity in vitro, peripheral blood lymphocyte lowering effects and the suppressive effects on adjuvant-induced arthritis and experimental autoimmune encephalomyelitis (EAE) in animal models. The pharmacokinetic data were also reported. CS-2100 (8) had >5000-fold greater agonist activity for human S1P(1) (EC50; 4.0 nM) relative to S1P(3) (EC50; >20000 nM). Following administration of single oral doses of 0.1 and 1 mg/kg of CS-2100 (8) in rats, lymphocyte counts decreased significantly, with a nadir at 8 and/or 72 h post-dose and recovery to vehicle control levels by 24-48 h post-dose. CS-2100 (8) is efficacious in the adjuvant-induced arthritis model in rats (ID50; 0.44 mg/kg). In the EAE model compared to the vehicle-treated group, significant decreases in the cumulative EAE scores were observed for 0.3 and 1 mg/kg CS-2100 (8) groups in mice. While CS-2100 (8) showed potent efficacy in various animal disease models, it was also revealed that the central 1,2,4-oxadiazole ring of CS-2100 (8) was decomposed by enterobacteria in intestine of rats and monkeys, implicating the latent concern about an external susceptibility in its metabolic process in the upcoming clinical studies. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.022
• 作为试剂：
  描述：

  、 {4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methanol 、 、 四溴化碳 、 三苯基膦 、 氮杂环丁烷-3-甲酸甲酯盐酸盐 、 N,N-二异丙基乙胺 在 methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate 、 crude product 作用下， 生成 、 methyl 1-({4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylate
  参考文献：
  名称：

  Heterocyclic compound

  摘要：

  具有低毒性的免疫抑制活性化合物或其药物盐。该化合物具有下面所示的一般式（I）或其药理学上可接受的盐或药理学上可接受的前药。

  公开号：

  US07687491B2

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1873153A1

  公开（公告）日：2008-01-02

  [Object] To provide a novel compound having an excellent immunosuppressive activity with low toxicity or a pharmacological salt thereof. [Means to achieve the object] A compound having general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof [wherein A represents a carboxyl group, or the like, B represents a hydrogen atom, or the like, V represents a single bond, a methylene group, or the like, n represents an integer of from 0 to 2, W represents a 5- to 7-membered heterocyclic group, or the like, Z represents a group selected from Substituent group A, or the like, and Substituent group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, a C3-C7 cycloalkyl group.

  目的 提供一种具有优异免疫抑制活性且毒性低的新型化合物或其药理盐。 [实现目标的方法］ 具有下图所示通式 (I) 的化合物或其药理学上可接受的盐，或其药理学上可接受的原药 其中 A代表羧基等，B代表氢原子等，V代表单键、亚甲基等，n代表0～2的整数，W代表5～7元杂环基等，Z代表选自取代基A等的基团，取代基A代表由卤素原子、C1～C6烷基、C3～C7环烷基组成的基团。
• 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1873153B1

  公开（公告）日：2010-07-07
• US7687491B2
  申请人：——

  公开号：US7687491B2

  公开（公告）日：2010-03-30
• Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist
  作者：Tsuyoshi Nakamura、Masayoshi Asano、Yukiko Sekiguchi、Yumiko Mizuno、Kazuhiko Tamaki、Takako Kimura、Futoshi Nara、Yumi Kawase、Takaichi Shimozato、Hiromi Doi、Takashi Kagari、Wataru Tomisato、Ryotaku Inoue、Miyuki Nagasaki、Hiroshi Yuita、Keiko Oguchi-Oshima、Reina Kaneko、Nobuaki Watanabe、Yasuyuki Abe、Takahide Nishi

  DOI：10.1016/j.bmcl.2011.12.019

  日期：2012.2

  S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P(1) and S1P(3) showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P(3), not in the case of Leu276 in S1P(1). This observation gives an explanation for the excellent S1P(3)-sparing characteristic of CS-2100. (C) 2011 Elsevier Ltd. All rights reserved.
• Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist
  作者：Tsuyoshi Nakamura、Masayoshi Asano、Yukiko Sekiguchi、Yumiko Mizuno、Kazuhiko Tamaki、Futoshi Nara、Yumi Kawase、Yoshiyuki Yabe、Daisuke Nakai、Emi Kamiyama、Yoko Urasaki-Kaneno、Takaichi Shimozato、Hiromi Doi-Komuro、Takashi Kagari、Wataru Tomisato、Ryotaku Inoue、Miyuki Nagasaki、Hiroshi Yuita、Keiko Oguchi-Oshima、Reina Kaneko、Takahide Nishi

  DOI：10.1016/j.ejmech.2012.02.022

  日期：2012.5

  Modulators of sphingosine phosphate receptor-1 (S1P(1)) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based S1P(1) agonist 1-(4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid (CS-2100, 8) showing potent S1P(1) agonist activity against S1P(3) and an excellent in vivo potency. We report herein the synthesis of CS-2100 (8) and pharmacological effects such as S1P(1) and S1P(3) agonist activity in vitro, peripheral blood lymphocyte lowering effects and the suppressive effects on adjuvant-induced arthritis and experimental autoimmune encephalomyelitis (EAE) in animal models. The pharmacokinetic data were also reported. CS-2100 (8) had >5000-fold greater agonist activity for human S1P(1) (EC50; 4.0 nM) relative to S1P(3) (EC50; >20000 nM). Following administration of single oral doses of 0.1 and 1 mg/kg of CS-2100 (8) in rats, lymphocyte counts decreased significantly, with a nadir at 8 and/or 72 h post-dose and recovery to vehicle control levels by 24-48 h post-dose. CS-2100 (8) is efficacious in the adjuvant-induced arthritis model in rats (ID50; 0.44 mg/kg). In the EAE model compared to the vehicle-treated group, significant decreases in the cumulative EAE scores were observed for 0.3 and 1 mg/kg CS-2100 (8) groups in mice. While CS-2100 (8) showed potent efficacy in various animal disease models, it was also revealed that the central 1,2,4-oxadiazole ring of CS-2100 (8) was decomposed by enterobacteria in intestine of rats and monkeys, implicating the latent concern about an external susceptibility in its metabolic process in the upcoming clinical studies. (C) 2012 Elsevier Masson SAS. All rights reserved.